Business
Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases
Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with
About this update from Gilead Sciences, Inc.
[{"type":"image","alt":"Accipiter Bio Logo","displaySize":"","headline":null,"caption":"Accipiter Bio Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/48a0e0bf7624f2ba3a8ebaf488bb7c68"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lMnIhiJyDlml28zSKofEBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/48a0e0bf7624f2ba3a8ebaf488bb7c68","width":300,"height":83}},"lazy":false},{"type":"text","content":"Strong syndicate of investors co-led by Takeda and Flying Fish Partners","length":71,"tagName":"p"},{"type":"text","content":"Proceeds will advance preclinical programs in immunology and oncology","length":69,"tagName":"p"},{"type":"text","content":"Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities","length":146,"tagName":"p"},{"type":"text","content":"SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with $12.7 million in seed financing. The round was co-led by Takeda and Flying Fish Partners, with participation from Columbus Venture Partners, Cercano Capital, Washington Research Foundation, Alexandria Investments, Pack Ventures and Argonautic Ventures.","length":469,"tagName":"p"},{"type":"text","content":"Accipiter Bio’s computational platform is paired with high-throughput experimentation to create custom, multifunctional de novo biologic therapeutics—entirely new proteins built from scratch rather than modified from those found in nature. These proteins are designed using proprietary computational methods to combine multiple mechanisms in a single, stable molecule and can be designed for any therapeutic application. In contrast to antibodies and multispecifics, which primarily block cellular pathways, Accipiter Bio’s biologics include agonists, precisely and specifically activating multiple pathways on the same cell simultaneously to leverage biological synergy. The platform also enables rapid iteration and accelerated therapeutic development, with in silico design-to-lab timelines of under two months.","length":814,"tagName":"p"},{"type":"text","content...